Mammoth Biosciences is a pioneering biotechnology company focused on leveraging CRISPR technology to revolutionize gene editing and diagnostics. With a strategic emphasis on developing in vivo gene editing therapeutics and advanced CRISPR-based diagnostics, Mammoth Biosciences aims to address significant unmet medical needs and enhance genetic medicine's potential.
Founded: 2017
Trevor Martin Co-founder and Chief Executive Officer |
Janice Chen Co-founder and Chief Technology Officer |
Lucas Harrington Co-founder and Chief Science Officer |
Jennifer Doudna Co-founder and Chair of Scientific Advisory Board |
Elaine Sun Chief Financial Officer and Chief Operating Officer |
Ted Tisch Chief Agility Officer |
Phil Tinmouth Chief Business and Strategy Officer |
BRISBANE, Calif.--(BUSINESS WIRE)--Jan 31, 2025-- Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new preclinical research, published on the preprint server bioRxiv, that establishes proof-of-concept of NanoCas
April 25 (Reuters) - Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.